5th Mar 2025 12:10
5 March 2025
BSF Enterprise PLC
("BSF" or the "Company")
Result of Annual General Meeting
BSF Enterprise (BSFE), through its 3D Bio-Tissues (3DBT) subsidiary, is transforming the biotech landscape with innovative technologies that include scaffold-free tissue engineered materials and patented macromolecular crowders, used as media additives to optimize cell growth.
The Company is pleased to announce that at the Company's Annual General Meeting held earlier today, all resolutions proposed were duly passed by shareholders by way of a poll, the results of which were as follows:
Resolution | Poll Results | |||||
For | Against | Withheld | Discretionary | Total | ||
1 | Shares | 74,812,766 | - | - | - | 74,812,766 |
% | 100.00% | - | - | - | 100% | |
2 | Shares | 73,512,766 | 1,309,210 | 10,000 | - | 74,831,976 |
% | 98.24% | 1.75% | - | - | 100% | |
3 | Shares | 73,512,766 | 1,309,210 | 10,000 | - | 74,831,976 |
% | 98.24% | 1.75% | - | - | 100% | |
4 | Shares | 60,137,512 | 1,756,487 | 10,000 | - | 61,903,999 |
% | 97.15% | 2.84% | - | 100% | ||
5 | Shares | 73,512,766 | 1,309,210 | 10,000 | - | 74,831,976 |
% | 98.24% | 1.75% | 0.01% | - | 100% | |
6 | Shares | 74,812,766 | - | 19,210 | - | 74,831,976 |
% | 99.97% | - | - | - | 100% | |
7 | Shares | 73,060,970 | 1,751,796 | 19,210 | - | 74,831,976 |
% | 97.63% | 2.34% | - | - | 100% | |
8 | Shares | 73,065,489 | 1,747,277 | 19,210 | - | 74,831,976 |
% | 97.64% | 2.33% | 0.03% | 100% | ||
9 | Shares | 74,812,766 | - | 19,210 | - | 74,831,976 |
% | 99.97% | - | 0.03% | - | 100% | |
About BSF Enterprise PLC:
BSF Enterprise PLC (BSF) is the parent to a portfolio of innovative subsidiary companies focused on developing and commercialising cell-based tissue engineering solutions to deliver sustainable outcomes across a variety of sectors. Its portfolio of subsidiaries is as follows:
- 3DBT: A pioneering UK-based tissue engineering company that has developed scaffold-free tissue production processes as well as leading on the commercial use of macromolecular crowders to transform cell culture.
- Lab-Grown Leather Ltd: A company focused on the customer driven development of cultivated skin technology to produce sustainable leather.
- Kerato Ltd: A tissue engineering company with patent-protected IP that is focussing on commercialising technologies for corneal repair with veterinary trials starting 2025 .
- BSF Enterprise (Hong Kong) Limited: A company established to actively support commercialisation of BSF's technology in China and Asia.
- Cultured Meat Technologies (CMT): A 100% owned company, using technology developed within 3DBT, successfully produced the UK's first high-quality cultivated meat. Currently focused on providing the market with the premier platform for manufacturing cultivated meat in a scalable and cost-competitive manner.
BSF's core strategy is to acquire, invest in, or develop joint ventures with, the most promising companies from across the industry. In doing so BSF intends to create an environment in which its portfolio of companies can flourish and collaborate, thereby accelerating their progress, potential and time to market.
For further enquiries, please visit www.bsfenterprise.com or contact:
Geoff Baker - Executive Director
Che Connon - CEO & Director
Shard Capital (Broker):
Damon Heath 0207 186 9000
Isabella Pierre 0207 186 9927
Related Shares:
Bio-Sustainable Future Enterprises